/ WHO WE ARE
RiverVest is a leading venture capital firm building life science companies to address significant unmet medical needs.
8
FUNDS
Since 2000
/ ACQUISITION
Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals
ST. LOUIS (December 8, 2025) – Bluejay Therapeutics – a RiverVest Venture Fund V portfolio company – has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a former RiverVest portfolio company focusing on rare liver diseases.
/ EXPERT INSIGHT
RiverVest Managing Director Niall O’Donnell discusses why taming a stress hormone might be the next breakthrough in type 2 diabetes care.
/ EXPERT INSIGHT
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility?
30
COMMERCIAL PRODUCTS
Currently Treating Patients
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.
Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.
© Copyright 2025 RiverVest® All Rights Reserved. | Privacy Policy
Subscribe to our newsletter